Full Text View
Tabular View
No Study Results Posted
Related Studies
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
This study is currently recruiting participants.
Verified December 2012 by Il-Yang Pharm. Co., Ltd.
Study NCT01511289   Information provided by Il-Yang Pharm. Co., Ltd.

First Received on January 3, 2012.   Last Updated on December 27, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Leukemia, Myeloid
Philadelphia Chromosome
Bone Marrow Diseases
Hematologic Diseases
Additional conditions recognized in this trial
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
More general conditions related to this trial
Chromosome Aberrations
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Translocation, Genetic
Interventions listed in this trial
Imatinib
Radotinib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Il-Yang Pharm. Co., Ltd.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services